Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the ...
Postoperative complications have been reported to be a risk factor for worse oncologic outcomes in patients with esophageal cancer. However, the impact of postoperative complications on prognosis ...
On November 22, 2024, PAVmed Inc. completed the sale of $21.95 million in principal amount of Lucid Diagnostics Inc.’s Senior Secured Convertible Notes, known as the “Lucid 2024 Convertible Notes,” in ...